 Clovis Oncology Inc. shares CLVS, -73.37 plunged 75 Wednesday, after the Colorado-based biotech said it will not have sufficient liquidity to maintain operations beyond January of 2023. The company said recent regulatory developments relating to its ovarian cancer drug Rubraca and challenges in raising fresh capital, a potential bankruptcy filing in the very near term looks increasingly probable as a way to preserve the value of our business and assets for the benefit of our stakeholders. 